S. Bohm et al., Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma, ONCOL-BASEL, 57(2), 1999, pp. 115-120
Based on previous clinical experience indicating the tolerability and effic
acy of high-dose cisplatin with glutathione protection in the treatment of
advanced ovarian cancer, this study was undertaken to explore the efficacy
and feasibility of an alternative high-dose, platinum-based approach includ
ing a combination of high-dose cisplatin plus carboplatin as induction chem
otherapy of advanced ovarian carcinoma and intervention surgery. Fifty cons
ecutive eligible patients with untreated stage III or IV epithelial ovarian
cancer received 40 mg/m(2) cisplatin daily on days 1-4 and 160 mg/m(2) car
boplatin on day 5. The cycle was repeated after 28 days. Patients received
glutathione (2,500 mg) before each cisplatin or carboplatin administration
and standard intravenous hydration. After 2 courses of induction chemothera
py, the patients underwent surgical reevaluation with debulking, when possi
ble, followed by a further 3 cycles of 120 mg/m(2) cisplatin (i.e. 40 mg/m(
2) daily for 3 consecutive days plus 600 mg/m(2) cyclophosphamide on day 3)
except in instances of lack of response. All eligible patients were assess
ed for response and toxicity. The toxicity was moderate with lack of signif
icant nephrotoxicity. Neurotoxicity and ototoxicity were acceptable and in
no patient was treatment discontinued for those toxic effects. Myelotoxicit
y was somewhat more severe than that observed with our previous study with
high-dose cisplatin and probably related to the addition of carboplatin. Of
the 40 responsive patients, 23 (46%) had a pathological complete response
and 4 (8%) had a clinical complete response (without second-look laparotomy
). The efficacy of the present protocol was also documented by overall surv
ival (median survival >48 months), which appeared to be better than expecte
d with the current therapy in this group with advanced/bulky disease. The i
mpressive efficacy suggests a possible contribution of reduced glutathione
itself in improving the outcome, as supported by preclinical studies. The r
esults of this study should be placed in context with current platinum-base
d therapy including paclitaxel.